SAB Biotherapeutics, Inc. - Common Stock (NQ:SABS)

SAB Biotherapeutics (NASDAQ:SABS) reaffirmed its timeline for completing enrollment in its pivotal Type 1 diabetes study by the end of 2026, as the company reported a wider research spending bill and a...

What SAB Biotherapeutics (SABS) Said on Its Q3 Earnings Call ↗

November 06, 2026

SAB Biotherapeutics (NASDAQ:SABS) Reports Q1 2026 Miss as Clinical Progress and Extended Cash Runway Through 2028 Take Center Stage ↗

Performance

52-Week Range 42.5% below 52-week high

2.960

2.4452W Low 5.1552W High

1 Week 8.4% below 1-week high

2.851W Low 3.231W High

SAB Biotherapeutics, Inc. - Common Stock (SABS) traded between $2.44 and $5.15 over the past 52 weeks and last traded at $2.96, 42.5% below its 52-week high. Over the past week it ranged between $2.85 and $3.23.

Past 12 Months

-4.5%

+14.3%

-21.5%

-16.9%

-21.5%

-8.6%

1W -$0.14

1M +$0.37

3M -$0.81

6M -$0.60

YTD -$0.81

1Y -$0.28

SABS was -8.6% over the past year, -16.9% over six months, -21.5% year to date, -4.5% in the last week.

12 Months vs Market

SABS

-8.6%

DIA

+10.9%

SPY

+12.3%

QQQ

+11.7%

IWM

+16.9%

Over the past 12 months SABS returned -8.6% versus DIA (Dow) +10.9%, SPY (S&P 500) +12.3%, QQQ (Nasdaq 100) +11.7% and IWM (Russell 2000) +16.9%.

Volume & Liquidity 1.11× 3-mo avg

Today 658,119 3-mo avg 593.6K

1.0M

688.0K

593.6K

640.0K

YTD

647.2K

600.3K

SABS most recently traded 658,119 shares against a 3-month average daily volume of 593.6K.

More News

SAB Biotherapeutics (SABS) Q3 2026 Earnings Call Transcript ↗

November 06, 2026

Via The Motley Fool

May 12, 2026

Via Chartmill

SAB BIO Reports Q3 2026 Financial Results and Provides Business Highlights

November 05, 2026

SAB BIO to Host Third Quarter 2026 Financial Results Conference Call and Webcast on November 5, 2026, 08:30 AM ET

October 29, 2026

SAB Biotherapeutics Highlights Diabetes Trial Progress, Human Antibody Platform ↗

October 23, 2026

SAB BIO to Participate in Chardan 10th Annual Healthcare Conference

October 14, 2026

SAB BIO Receives FDA Fast Track Designation for SAB-142 in Stage 3 Type 1 Diabetes

October 13, 2026

SAB BIO to Present SAB-142 Data at the Inaugural Breakthrough T1D Clinical & Research Congress

October 01, 2026

SAB BIO to Present SAB-142 Data at the 62nd Annual Meeting of the European Association for the Study of Diabetes

September 22, 2026

SAB BIO to Participate in Upcoming Investor Conferences

September 01, 2026

SAB Biotherapeutics Q2 Earnings Call Highlights ↗

August 07, 2026

SAB BIO Reports Q2 2026 Financial Results and Provides Business Highlights

August 06, 2026

SAB BIO to Host Second Quarter 2026 Financial Results Conference Call and Webcast on August 6, 2026, 08:30 AM ET

July 30, 2026

Breakthrough T1D Awards Grant to Support PRISE‑hATG Study of SAB‑142 in Stage 3 Type 1 Diabetes

July 07, 2026

SAB BIO to Present Data on SAB-142 at The American Diabetes Association’s 2026 Scientific Sessions and FOCIS 2026 Annual Meeting

May 29, 2026

SAB Biotherapeutics Q1 Earnings Call Highlights ↗

May 12, 2026

SAB BIO Reports Q1 2026 Financial Results and Recent Business Highlights

May 12, 2026

SAB BIO to Host First Quarter 2026 Financial Results Conference Call and Webcast on May 12, 2026, 08:30 AM ET

May 05, 2026

Emergent BioSolutions Secures Long-Term Strategic Manufacturing Contract with SAB Biotherapeutics to Advance Type 1 Diabetes Candidate, SAB-142

April 29, 2026

From Emergent BioSolutions

SAB BIO Presents Additional Clinical and Mechanistic Data from SAB-142 Phase 1 Trial in Adult Patients with Established Autoimmune Type 1 Diabetes at IDS 2026

April 22, 2026

SAB BIO to Present Additional Data Supporting the Unique Profile of SAB-142 at the 2026 Immunology of Diabetes Society Congress

April 15, 2026

SAB BIO Announces Closing of $85 Million Public Offering of Common Stock and Pre-Funded Warrants

March 19, 2026

SAB BIO Announces Pricing of $85 Million Public Offering of Common Stock and Pre-Funded Warrants

March 17, 2026